The FDA has accepted a biologics license application for ivonescimab, a treatment for patients with EGFR-mutated non-small cell lung cancer. The application seeks approval for ivonescimab in combination with chemotherapy for patients who have undergone tyrosine kinase inhibitor therapy, although the specific timing of this treatment in the patient's regimen is not uniformly described. The FDA's acceptance marks the start of the review process for this potential treatment.